Kazumasa Kotake

Mr. Kazumasa Kotake

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Journal of Pharmacy Technology
Verified
Journal Article
Closed access
KKKazumasa Kotake
Kazumasa Kotake
SMSatoru Mitsuboshi
Satoru Mitsuboshi
YOYuki Omori
Yuki Omori
YKYukio Kawakami
Yukio Kawakami
YKYasuhiro Kawakami
Yasuhiro Kawakami
Background: Romosozumab is associated with an increased risk of cardiac or cerebrovascular events. Identifying the risk factors for these events could contribute to the safe use of romosozumab. Objective: This study aimed to investigate risk factors for cardiac or cerebrovascular events in romosozumab users. Methods: First, disproportionality analysis was performed to compare the frequency of cardiac or cerebrovascular events, using data from the Japanese Adverse Drug Event Report database. Next, multivariate logistic analysis was performed to investigate risk factors for cardiac or cerebrovascular events in romosozumab users. Results: In total, 859 romosozumab users were identified. A disproportionality of both cardiac and cerebrovascular events was observed in only romosozumab users. Multivariate logistic analysis revealed that the risk of cardiac events in romosozumab users was significantly increased in patients with cardiac disease (odds ratio [OR]: 5.9, 95% confidence interval [CI] 3.5-9.9; P < 0.01) and hypertension (OR: 1.6, 95% CI 1.0-2.7; P = 0.047). In addition, the risk of cerebrovascular events in romosozumab users was significantly increased in the presence of cerebrovascular disease (OR: 2.7, 95% CI 1.2-6.2; P = 0.02) and hypertension (OR: 2.6, 95% CI 1.7-3.9; P < 0.01). Conclusion: Our findings suggest that hypertension may increase the risk of cardiac or cerebrovascular events in romosozumab users. Although additional studies are needed to assess other associated factors, these findings may contribute to the appropriate use of romosozumab and limit adverse events.



Verified
Journal Article
Open access
PDF file
AYAkiko Yamada
Akiko Yamada
AWAkira Watanabe
Akira Watanabe
ANAtsushi Nara
Atsushi Nara
NINaozumi Ishimaru
Naozumi Ishimaru
KMKosuke Maeda
Kosuke Maeda
TYTakenori Yamamoto
Takenori Yamamoto
Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases worldwide. Some patients with MAFLD develop metabolic dysfunction-associated steatohepatitis (MASH), which can lead to severe liver fibrosis. However, the molecular mechanisms underlying this progression remain unknown, and no effective treatment for MASH has been developed so far. In this study, we performed a longitudinal detailed analysis of mitochondria in the livers of choline-deficient, methionine-defined, high-fat-diet (CDAHFD)-fed mice, which exhibited a MASH-like pathology. We found that FoF1–ATPase activity began to decrease in the mitochondria of CDAHFD-fed mice prior to alterations in the activity of mitochondrial respiratory chain complex, almost at the time of onset of liver fibrosis. In addition, the decrease in FoF1–ATPase activity coincided with the accelerated opening of the mitochondrial permeability transition pore (PTP), for which FoF1–ATPase might be a major component or regulator. As fibrosis progressed, mitochondrial permeability transition (PT) induced in CDAHFD-fed mice became less sensitive to cyclosporine A, a specific PT inhibitor. These results suggest that episodes of fibrosis might be related to the disruption of mitochondrial function via PTP opening, which is triggered by functional changes in FoF1–ATPase. These novel findings could help elucidate the pathogenesis of MASH and lead to the development of new therapeutic strategies.

10 May 2025 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
KKKazumasa Kotake
Kazumasa Kotake
RSRyuhei So
Ryuhei So
NHNozomu Hashimoto
Nozomu Hashimoto
EIEriya Imai
Eriya Imai
TKTakao Kaneko
Takao Kaneko
YFYuki Furukawa
Yuki Furukawa

22 November 2024 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
SMSatoru Mitsuboshi
Satoru Mitsuboshi
MMMakoto Morizumi
Makoto Morizumi
SIShungo Imai 
Shungo Imai 
SHSatoko Hori
Satoko Hori
KKKazumasa Kotake
Kazumasa Kotake